Welcome to our dedicated page for Anavex Life Scie news (Ticker: AVXL), a resource for investors and traders seeking the latest updates and insights on Anavex Life Scie stock.
Anavex Life Sciences Corp. reports developments as a clinical-stage biopharmaceutical company focused on central nervous system disorders, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome, and other neurodevelopmental, neurodegenerative, and rare diseases. Company news frequently centers on blarcamesine, its orally administered lead candidate, along with precision-medicine analyses using genomic and biomarker data.
Recurring updates include clinical and preclinical data presentations, scientific findings related to autophagy, synaptic dysfunction, SIGMAR1 biology, and disease mechanisms, as well as regulatory communications with the FDA and EMA. News also covers financial results, healthcare conference participation, board composition, executive leadership changes, and other corporate governance matters.
Anavex Life Sciences Corp. (Nasdaq: AVXL) reported its financial results for the fiscal year ending September 30, 2021. The company has a strong cash position of $152.1 million, significantly up from $29.2 million in 2020. However, it reported a net loss of $37.9 million (or $0.54 per share), worsening from $26.3 million (or $0.45 per share) the previous year. Anavex is advancing three clinical trials, with top-line results expected in late 2021 and 2022 for Alzheimer's and Rett syndrome treatments. The company aims for growth through its SIGMAR1 platform.
Anavex Life Sciences Corp. (Nasdaq: AVXL) will announce its fiscal year financial results for the period ended September 30, 2021, during a conference call on November 24, 2021, at 4:30 PM EDT. The call will provide insights into the company's growth strategy.
Founded to develop therapeutics for neurodegenerative disorders, Anavex's lead candidate, ANAVEX®2-73, has shown promising results in clinical trials for conditions like Alzheimer’s and Parkinson’s diseases. The event will include a Q&A session following management’s remarks.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced that CEO Christopher U. Missling will participate in the Lausanne VIII Workshop for Leaders and Innovators in Alzheimer’s from November 15 to 18, 2021. The workshop, focusing on novel therapeutic approaches, aims to address Alzheimer’s disease challenges and promote solutions by 2025. The event, organized by OECD and supported by various international organizations, highlights the growing urgency of Alzheimer's, which currently affects 5.7 million Americans and is projected to cost $1.1 trillion by 2050.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced that CEO Christopher U. Missling, PhD, will present at the Dawson James Securities 6th Annual Conference on October 21, 2021, at 1:30 PM ET. Anavex focuses on developing therapeutics for neurodegenerative disorders like Alzheimer’s and Parkinson’s diseases. Their lead candidate, ANAVEX®2-73, has shown promise in clinical trials, including a Phase 2 for Alzheimer's. The company will provide a webcast of the presentation on its website, accessible for 30 days.
Anavex Life Sciences Corp. (AVXL) announced positive progress in its Phase 2b/3 Alzheimer’s disease study of ANAVEX®2-73 (blarcamesine). The Independent Data Safety Monitoring Board (DSMB) recommended continuing the trial without modifications after reviewing interim safety data. The study, which has fully enrolled 509 patients, is centered on assessing safety and cognitive function, using primary endpoints like ADAS-Cog. Topline data is expected in the second half of 2022, with potential implications for treating neurodegenerative disorders.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced that its CEO, Christopher U. Missling, PhD, will participate in a panel at the 5th Pharma Pricing, Reimbursement & Market Access 2021 conference on September 29, 2021. The discussion will focus on drug development for Fragile X Syndrome through community-based collaboration. Anavex specializes in developing therapeutics for neurodegenerative disorders such as Alzheimer's and Parkinson's disease, with its lead drug candidate, ANAVEX®2-73, showing promising results in clinical trials for these conditions.
Anavex Life Sciences Corp. (NASDAQ: AVXL) announced its uplisting to the NASDAQ Global Select Market, effective September 27, 2021. This marks a significant achievement for Anavex, previously listed on the NASDAQ Capital Market, highlighting the company's compliance with stringent financial and governance standards. President & CEO, Christopher U Missling, emphasized this transition as a reflection of the company's growth and long-term potential. Anavex focuses on developing therapeutics for neurodegenerative disorders, with its lead candidate, ANAVEX®2-73, showing promising results in clinical trials.
Anavex Life Sciences Corp. (Nasdaq: AVXL) will present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021, at 10:40 AM (ET). The company specializes in developing therapeutics for neurodegenerative disorders, including Alzheimer’s, Parkinson’s, and Rett syndrome. Anavex's lead drug candidate, ANAVEX®2-73, has shown promise in clinical trials, demonstrating potential benefits for both Alzheimer’s and Parkinson’s disease. The live audio webcast of the presentation will be available on the company’s website and will be accessible for 30 days post-event.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced that CEO Christopher U. Missling, PhD, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. A webcast of the on-demand presentation will be available starting September 13 at 7:00 A.M. (ET) through their website and the conference platform. Anavex specializes in therapeutics for neurodegenerative disorders, having successfully completed clinical trials for its lead drug candidate ANAVEX®2-73, designed for Alzheimer’s and Parkinson’s diseases.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced the publication of preclinical data on ANAVEX®2-73 (blarcamesine) for treating Fragile X Syndrome in Scientific Reports. The study demonstrated the drug's ability to reverse hyperactivity, restore associative learning, and reduce anxiety in Fmr1 knockout mice. Positron emission tomography confirmed dose-dependent receptor occupancy. These findings pave the way for a Phase 2/3 clinical trial, potentially expanding treatment options for the 62,500 Fragile X patients in the US.